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ABSTRACT
Objectives: Dementia with Lewy bodies (DLB)
accounts for 10%e15% of dementia cases at autopsy
and has distinct clinical features associated with earlier
institutionalisation and a higher level of carer distress
than are seen in Alzheimer’s disease (AD). At present,
there is on-going debate as to whether DLB is
associated with a more rapid cognitive decline than
AD. An understanding of the rate of decline of
cognitive and non-cognitive symptoms in DLB may
help patients and carers to plan for the future.
Design: Inthiscohortstudy,theauthorscompared100
AD and 58 DLB subjects at baseline and at 12-month
follow-up on cognitive and neuropsychiatric measures.
Setting: Patients were recruited from 40 European
centres.
Participants: Subjects with mildemoderate dementia.
Diagnosis of DLB or AD required agreement between
consensus panel clinical diagnosis and visual rating of
123I-FP-CIT (dopamine transporter) single photon
emission computed tomography neuroimaging.
Outcome measures: The Cambridge Cognitive
Examination including Mini-Mental State Examination
and Neuropsychiatric Inventory (NPI).
Results: The AD and DLB groups did not differ at
baseline in terms of age, gender, Clinical Dementia
Rating score and use of cholinesterase inhibitors or
memantine. NPI and NPI carer distress scores were
statistically signiﬁcantly higher for DLB subjects at
baseline andat follow-up, andtherewereno differences
between AD and DLB in cognitive scores at baseline or
at follow-up. There was no signiﬁcant difference in rate
of progression of any of the variables analysed.
Conclusions: DLB subjects had more
neuropsychiatric features at baseline and at follow-up
than AD, but the authors did not ﬁnd any statistically
signiﬁcant difference in rate of progression between
the mildemoderate AD and DLB groups on cognitive
or neuropsychiatric measures over a 12-month
follow-up period.
INTRODUCTION
Dementia with Lewy bodies (DLB) is
the second most common form of neurode-
generative dementia and accounts for
approximately 15% of cases of dementia at
autopsy.
1 It is characterised by the central
feature of a progressive dementia accompa-
nied by one or more core features of ﬂuctu-
ations in cognition, visual hallucinations and
spontaneous features of parkinsonism.
2
Awareness of the rate of cognitive decline
and also of non-cognitive symptoms can help
carers and patients to adjust and plan
appropriate lifestyle changes and to make
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ARTICLE SUMMARY
Article focus
- Dementia with Lewy bodies (DLB) has distinct
neuropsychiatric features
- At present, we do not know whether the poorer
prognosis of DLB is due to a more rapid
cognitive decline compared with Alzheimer’s
disease (AD)
Key messages
- In this fairly large cohort of patients with DLB
and AD, while there was no difference in level of
cognitive impairment (Cambridge Cognitive
Examination (CAMCOG) score) at baseline and
at 12-month follow-up, DLB patients had signif-
icantly higher Neuropsychiatric Inventory (NPI)
and NPI carer distress scores both at baseline
and at 12-month follow-up.
- Therefore, the worse prognosis of DLB is likely to
be mediated by neuropsychiatric or other
symptoms and not only by cognitive decline
Strengths and limitations of this study
- Inclusion of high number of subjects from 40
European clinical centres
- Well-characterised cases with both consensus
panel clinical diagnosis (three clinical experts)
and dopaminergic transporter single photon
emission computed tomography imaging
- No autopsy data were available and therefore it is
possible that more rapid cognitive decline may
be present in pure DLB
- Only 1 year of follow-up
- There was higher attrition rate (no-follow-up
assessment) in the DLB group, and DLB patients
that did not return for follow-up were more
impaired than AD patients.
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Open Access Researcharrangements for the future. This frequently involves
making difﬁcult decisions regarding treatment of
psychiatric and motor symptoms and utilisation of
limited resources available for patients with dementia.
Since its recognition as a neurodegenerative disorder,
a body of research has focused on the differentiation of
DLB from other dementias, in particular Alzheimer’s
disease (AD), in terms of both cross-sectional and
longitudinal clinical factors. In addition to the clinical
syndrome described in the consensus diagnostic criteria,
DLB is associated with higher levels of behavioural
disturbance and care giver distress, lower quality of life
and greater demand on resources when compared with
AD.
3 4 Despite these ﬁndings, there is uncertainty within
the literature regarding progression and survival in DLB
compared with AD. Studies have shown survival in DLB
to be either comparable to
5 or shorter
6 than in AD. No
differences in decline on global measures (eg, Clinical
Dementia Rating (CDR)) have been reported.
7 Studies
of the progression of cognitive impairment have gener-
ally reported a similar
78or steeper
5 rate of decline in
DLB when compared with AD. An exception to this was
a study by Stavitsky et al
9 where AD patients had a steeper
decline on cognitive and behavioural measures, although
DLB patients had been more impaired at baseline.
Comparisons of longitudinal outcomes between DLB
and AD to date have generally needed to trade off
diagnostic accuracy against prospective study design.
Autopsy studies have the beneﬁt of deﬁnitive diagnosis
but are usually dependent on retrospective analysis of
clinical data. Studies using clinical diagnosis often have
the advantage of prospective study design but at the
expense of diagnostic accuracy. Overall, the majority of
studies of the 1996 clinical consensus criteria for DLB
10
have identiﬁed high speciﬁcity, with lower estimates of
sensitivity. While one study identiﬁed 83% sensitivity
and 95% speciﬁcity, estimates of sensitivity from other
studies have been as low as 23%
11 12 with reports of
speciﬁcity ranging from 8% to 100%; the most frequent
misdiagnosis of DLB is as AD.
13
Thedevelopmentof
123I-FP-CITsinglephotonemission
computed tomography (SPECT) now allows visualisation
of striatal dopamine transporter, and consequentially
dopaminergic degeneration in vivo, and differentiates
between AD and DLB with a sensitivity and speciﬁcity of
78%e88% and 94%e100%, respectively.
14 An abnormal
visual rating on
123I-FP-CIT SPECTwas incorporated into
the most recent revision of the consensus diagnostic
criteria.
2 In the present study, our aim was to compare
decline in cognitive, behavioural and global measures
overa12-monthperiodinaprospectivelyfollowedcohort
ofsubjectswitheitherADorDLBconﬁrmedbyconsensus
panel clinical diagnosis and normal (for AD) and
abnormal (for DLB)
123I-FP-CIT SPECT imaging.
METHODS
Data were collected as part of a phase 3 multicentre
imaging study whose methodology is described in detail
elsewhere.
15 16 In brief, patients were aged 55e90 years
and met the criteria for dementia detailed in DSM-IV
and fulﬁlled at least one of the following: consensus
criteria for DLB,
10 NINCDS-ADRDA criteria for probable
or possible AD
17 or NINDS/AIREN criteria for probable
or possible vascular dementia.
18 A Mini-Mental State
Examination (MMSE) score at baseline of $10 was
required to ensure patients could complete assess-
ments.
19 Patients with dementia who developed parkin-
sonism >1 year before the onset of dementia were
deemed to have Parkinson’s disease with dementia and
were not included.
10 Those with structural imaging
ﬁndings indicative of infarction in the region of the
basal ganglia, including the internal capsule, were
excluded. Use of medication known or suspected to
interact with striatal binding of
123I-FP-CIT was not
permitted.
20
The study was done in accordance with the current
revision of the Declaration of Helsinki and the Good
Clinical Practice: Consolidated Guideline approved by
the International Conference on Harmonisation and
applicable to national and local laws and regulations. At
every participating site, the study protocol and all
amendments were approved by an institutional review
board or independent ethics committee. All patients and
care givers gave written informed consent.
Following inclusion in the initial study, participants
were invited for clinical and neuropsychological re-
assessment at 12 months.
Clinical diagnosis at baseline, as previously reported,
was established by an independent consensus panel of
three specialist clinicians, who were provided with
a patient proﬁle compiled from quality-assured clinical
data from the on-site investigators’ case record forms
and copies of on-site original source data.
15 The same
panel reconvened to consider the baseline and the
12-month follow-up data to arrive at a second and ﬁnal
consensus diagnosis. This ﬁnal consensus diagnosis was
used to derive the cohort for the present study.
The following were undertaken at baseline and follow-
up: MMSE, Uniﬁed Parkinson’s Disease Rating Scale III
(motor section),
21 modiﬁed Hoehn and Yahr staging,
22
clinical assessment of cognitive ﬂuctuation scale,
23 the
Cambridge Cognitive Examinationdrevised version
(CAMCOG-R),
24 Neuropsychiatric Inventory with care
giver input (NPI-D),
25 visual object and space perception
(VOSP) battery
26 and CDR.
27 The Cornell Scale for
Depression in Dementia
28 and the investigator’s esti-
mation of the patient’s IQ level were completed at
baseline but not at follow-up. Results of MRI and CT
scans and the on-site investigators’ clinical diagnosis
before imaging were also available. The consensus panel
did not have access at any stage to
123I-FP-CIT SPECT
ﬁndings and was unaware of the patients’ identities and
the names of the centres and the investigators. Before
any cases were diagnosed, the consensus panel was asked
to diagnose 10 patients (separate to the study) for whom
autopsy diagnosis was independently available. There
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the panel and at autopsy.
15 Individual panel members
reviewed each study case, including the baseline
consensus panel diagnosis and all subsequent informa-
tion, before meeting to agree a ﬁnal clinical diagnosis of
probable DLB, possible DLB or non-DLB dementia.
Patients in the non-DLB category were further allocated
to probable or possible AD, probable or possible vascular
dementia or other.
Within a few weeks of the baseline clinical diagnosis,
SPECT images were acquired on a 2 or 3 headed g
camera (SPECT system) 3e6 h after a single intravenous
injection of 111-185 MBq of
123I-FP-CIT
29 (DaTSCAN,
the radiotracer was supplied by GE Healthcare Buchler
GmbH & Co. KG, Munich, Germany). See McKeith et
al
15 for details. Subjects underwent standard thyroid
blocking. SPECT imaging was not repeated at follow-up.
As previously described, three nuclear medicine physi-
cians assessed scans, blind to diagnosis, using a 4-point
scale (0, normal uptake; 1, unilateral putamen loss; 2,
bilateral putamen loss and 3, virtually absent uptake)
15;
we used only the dichotomous division of normal (0)
versus abnormal (1e3) images for analysis. For the
present study, we combined the three independent reads
and recorded the result of the scan as normal or
abnormal if there was agreement between two or more
raters.
For the purposes of the present study, we included
only patients with complete data sets from both baseline
(T1) and 1-year follow-up (T2) assessments and with
reliable images from the baseline
123I-FP-CIT SPECT
session (n¼225). These patients were divided into two
diagnostic groups (AD and DLB). Inclusion criteria for
the AD group were a consensus diagnosis of possible or
probable AD at 12-month follow-up in addition to
a negative (normal)
123I-FP-CIT SPECT read (n¼100).
To be included in the DLB group, patients were required
to have a consensus diagnosis of probable DLB at 12-
month follow-up and to have a positive (abnormal)
123I-FP-CIT SPECT image read (n¼58). Patients with
a dementia diagnosis other than possible or probable AD
or probable DLB were excluded (n¼50), see ﬂowchart in
ﬁgure 1.
STATISTICAL ANALYSIS
Data were analysed using SPSS V.18. We compared
baseline and 12-month follow-up data and change over
time for the AD and DLB groups. c
2 tests were used to
assess differences between the diagnostic groups (AD
and DLB) with respect to gender and medication use at
baseline. For normally distributed variables, t tests were
used for between-group comparisons of baseline and
follow-up variables. ManneWhitney U tests were used for
non-normally distributed baseline and follow-up data.
Figure 1 Flowchart of subjects
included in the study. The
ﬂowchart details patients who
completed both baseline and
follow-up assessments. Twenty-
ﬁve patients with a diagnosis of
dementia with Lewy bodies (DLB)
at baseline and 19 patients with
a diagnosis of Alzheimer’s
disease (AD) at baseline did not
return for follow-up and are
therefore not included in the
ﬂowchart.
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analysis of group 3 time interactions (comparison of
change in variables over time in each group).
General Linear Models with ﬁxed effect were used to
adjust for the difference in NPI scores and the scores
on the Cornell Scale for Depression in Dementia at
baseline.
RESULTS
Baseline and follow-up data for the DLB and AD groups
are presented in table 1. The groups did not differ in
terms of age or gender. There were no between-group
baseline differences in terms of CDR or use of cholin-
esterase inhibitors or memantine. The DLB group had
a statistically signiﬁcantly higher mean depression score
at baseline and higher scores on the NPI, NPI carer
distress and clinical assessment of cognitive ﬂuctuation
scales at both baseline and 12-month follow-up
(p<0.001). There were no differences between the
groups on cognitive scores at either baseline or follow-
up. No signiﬁcant differences in change in scores
between baseline and 12-month follow-up for any of the
variables analysed were identiﬁed. Results of analysis did
not change when data were stratiﬁed according to
gender. There was also no statistically signiﬁcant differ-
ence between DLB and AD in the change of CAMCOG
score after adjustment for scores on NPI and Cornell
Scale for Depression scores. There were numerically
greater changes (more decline) between baseline and
follow-up on cognition, ﬂuctuation and on measures of
neuropsychiatric symptoms in the DLB patients but this
did not reach statistical signiﬁcance. The lack of
a signiﬁcant difference on the cognitive performance
between the DLB and AD groups is unlikely to be due to
lack of power, therefore type II error, as the effect size of
that difference was very small (0.02e0.07) and only
a sample size of 1685 subjects would have shown
a signiﬁcant difference.
A higher number of DLB patients (25) compared with
AD patients (19) did not return for a follow-up visit. DLB
Table 1 Baseline characteristics and scores on clinical scales and cognitive testing at baseline and at 12-month follow-up and
change in scores between time points for Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) groups
AD (n[100) DLB (n[58) p
Gender (M:F)
M 48 (48%) 37 (64%) 0.06
F 52 (52%) 21 (36%)
Age in years at
123I-FP-CIT SPECT session 74.9 (7.3) 74.2 (6.1) 0.53
Cornell Scale for Depression in Dementia (baseline) 3.8 (3.3) 6.6 (3.4) <0.001
Cholinesterase inhibitor 82 (82%) 45 (76%) 0.50
Memantine 9 (9%) 2 (3%) 0.19
Neuroleptic medication 4 (4%) 9 (16%) 0.01
Clinical Dementia Rating (baseline) 1.2 (0.69) 1.3 (0.66) 0.3
MMSE score (SD)
Baseline 21.5 (4.5) 21.4 (3.9) 0.85
Follow-up 19.0 (6.2) 18.5 (6.0) 0.65
Change 2.6 (4.0) 3.1 (4.3) 0.40
CAMCOG score (SD)
Baseline 66.3 (15.6) 66.0 (13.5) 0.89
Follow-up 59.5 (20.3) 56.3 (19.7) 0.35
Change 7.5 (10.6) 9.0 (11.9) 0.429
NPI score (SD)
Baseline 9.7 (10.3) 19.8 (14.6) <0.001
Follow-up 12.3 (13.3) 24.2 (17.4) <0.001
Change 2.5 (14.8) 3.8 (15.5) 0.59
NPI-carer score (SD)
Baseline 5.8 (6.0) 10.8 (8.0) <0.001
Follow-up 5.8 (5.7) 11.8 (8.6) <0.001
Change  0.05 (6.4) 0.8 (7.1) 0.44
Fluctuations
Baseline 0.6 (2.1) 6.0 (4.5) <0.001
Follow-up 0.4 (1.7) 6.9 (4.1) <0.001
Change  0.2 (2.4) 0.8 (4.1) 0.07
CAMCOG executive function
Baseline 11.9 (5.2) 11.1 (4.7) 0.33
Follow-up 10.5 (5.4) 9.4 (5.0) 0.24
Change 1.5 (3.6) 1.4 (4.0) 0.83
Data are presented as mean (SD) or number (%). p¼p Values (analysis of variance).
CAMCOG, Cambridge Cognitive Examination; MMSE, Mini-Mental State Examination; NPI, Neuropsychiatric Inventory.
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tively impaired than AD patients lost to follow-up at
baseline on MMSE (score 17.3 vs 22.2), CAMCOG (score
53.1 vs 66.7) and executive function (score 8.4 vs 13.3).
Since these patients lost to follow-up were not given
a ﬁnal diagnosis, they were not included in the main
analysis.
DISCUSSION
In a prospectively followed sample of patients with clin-
ical consensus panel and dopamine transporter SPECT
conﬁrmed diagnosis of AD or DLB, cross-sectional
assessments identiﬁed expected between-group similari-
ties and differences in cognitive scores and clinical scales
in addition to a higher level of carer distress relating to
the symptoms of DLB patients. We identiﬁed no differ-
ences in rate of progression of cognitive or neuropsy-
chiatric variables over a 12-month follow-up period. Our
inclusion of only patients whose consensus clinical
diagnosis was in keeping with neuroimaging results
make it likely that diagnostic accuracy was very high.
The AD and DLB groups were well matched in terms
of age and degree of cognitive impairment at baseline.
The ﬁnding that patients with DLB had higher scores on
the NPI, clinician assessment of ﬂuctuation and Cornell
Scale for Depression in dementia were expected given
the recognised diagnostic criteria.
2
NPI score was higher at both time points in DLB,
despite similar cognitive and baseline CDR scores; this
was associated with higher levels of care giver distress
and is in keeping with other published data.
4 30 Severity
of neuropsychiatric symptoms in AD
31 and DLB
32 has
been shown to be a predictor of both care giver distress
and nursing home placement. Care giver distress has
also been shown to be an independent risk factor for
nursing home placement in dementia.
33 It is possible
that the shorter time to nursing home placement that
has been reported in DLB compared with AD
34 is related
to neuropsychiatric symptoms and associated care giver
distress. Not all studies are consistent, however, and
marginal
6 or no differences
8 in time to placement
have also been reported. Furthermore, costs of care in
DLB and AD have been shown to correlate with
impairments in activities of daily living (ADLs) and not
NPI scores.
4
Severity of neuropsychiatric symptomatology, and
hallucinations in particular, has also been associated with
steeper decline in cognitive scores and increased risk of
mortality and institutionalisation in AD, independent of
antipsychotic drug use.
35 36 These studies have lacked
autopsy conﬁrmation of diagnosis, and it is possible that
the AD groups included individuals with undiagnosed
DLB, who are more likely to experience hallucinations.
We are not aware of any published data related to the
impact of neuropsychiatric symptom severity on illness
progression and survival in DLB.
We did not identify any between-group differences in
change over time of any of the variables examined, that
is, NPI, ﬂuctuations and cognitive performance. It is
possible that the lack of detectable difference in decline
of NPI and ﬂuctuation scores over time is related to the
already high scores at baseline in DLB. The majority of
studies of the rate of cognitive decline in DLB versus AD
have also reported no differences, for example,
7 8
although the earliest reports were of more rapid decline
in cognition in DLB,
37 as were more recent studies.
5
Several studies have reported relatively preserved
cognitive scores, particularly in recall, before death in
DLB compared with AD.
5 As mentioned in ‘Results’,
patients diagnosed as having DLB at baseline who were
lost to follow-up were signiﬁcantly more cognitively
impaired than patients diagnosed as having AD at base-
line who were lost to follow-up. These patients were not
included in the ﬁnal analysis, as the cohort analysed was
derived from the ﬁnal consensus diagnosis made at
follow-up. Thus, although patients lost to follow-up
appeared to differ cognitively depending on diagnosis
and this could have affected the study’s results, their
diagnoses were not made at the same time point as for
the patients included in the ﬁnal cohort. Reviewing the
characteristics of patients lost to follow-up must there-
fore be done tentatively, as their diagnoses were subject
to change.
It has been suggested that DLB may be associated with
a more rapid decline in global measures of dementia
severity or measures of ADLs while cognitive perfor-
mance is relatively preserved. However, no signiﬁcant
differences in change in CDR score over time between
the DLB and AD groups have yet been identiﬁed.
7 We
did not examine performance on ADLs. Cross-sectional
assessments of activities of living have reported higher
levels of impairment in DLB than in AD,
93 0which
may be related to extrapyramidal motor symptoms.
38
Longitudinal data, however, suggest no difference or
a marginal difference in rate of decline of ADLs between
AD and DLB.
9
While ours and the majority of studies do not support
the idea of a more rapid decline in cognition in DLB,
the available literature is split more evenly between
ﬁndings of either similar or shorter survival in DLB
compared with AD. One possibility is that reports of
worse outcomes in DLB are related to increased
frequency of antipsychotic use as a result of greater
severity of neuropsychiatric symptoms. While more DLB
than AD participants were prescribed neuroleptics in the
present study, no differences in rate of progression were
identiﬁed. Previous studies of cognitive decline in AD
and DLB that have presented data on neuroleptic
prescribing did not report any differences between the
groups in use of these medications.
8 39 In terms of
survival, both early
40 and more recent
68studies have
reported shorter survival in DLB versus AD, despite likely
changes in neuroleptic prescribing over this time as
a result of better understanding of the potentially
harmful effects in both DLB
21 0and dementia as
a whole. It therefore seems unlikely that reported
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entirely accounted for by antipsychotic use.
The literature surrounding the differences in longi-
tudinal outcomes in DLB and AD is therefore not easy to
interpret. Overall, studies report outcomes in DLB that
are either no different from or worse than in AD. Some
of the difﬁculties involved in interpreting and
comparing these ﬁndings are the differences in study
design, use of clinical rather than pathological diagnosis,
differing pathological deﬁnitions and retrospective
analysis of clinical data. In addition, studies often rely on
relative’s reports on the onset of dementia, or use as
baseline the time of referral, diagnosis or entry into the
study. None of these methods necessarily identify
equivalent disease stages and these difﬁculties highlight
the complexity of the task of comparing the rate of
decline between two disorders with different clinical
phenotypes. In DLB, episodic memory is relatively
spared in the early stages, but the presence of attentional
and visuospatial impairments, visual hallucinations or
movement disorder might be more disabling. Compari-
sons between AD and DLB are therefore not
straightforward, and it is hard to deﬁne what is an
‘equivalent’ disease stage. The picture is further
complicated by the frequent overlap of AD and DLB
neuropathology and the insidious onset of both of these
conditions.
Our study would have been improved by a longer
duration of follow-up and a more detailed breakdown of
cognitive, behavioural and clinical measures. Further-
more, patients’ ability to carry out ADLs was not
measured, and this can be a useful marker of disease
severity and progression. Exclusion of individuals with
severe dementia and higher attrition (not returning for
follow-up visit) of DLB cases with more severe cognitive
impairment precluded detection of differences in
progression that are present only in later disease stages.
Larger cohorts of patients who could be stratiﬁed by
stages of severity of dementia are needed to examine this
possibility. The DLB group had a higher mean depres-
sion score at baseline and more patients took a neuro-
leptic. Both neuroleptics and antidepressants have
been shown to have detrimental effect on patients
with dementia and could lead to faster progression but
this did not seem to be the case over the duration of
1 year. Without autopsy diagnosis, we were not able to
differentiate patients with pure and combined
pathology.
In conclusion, on global cognitive measures, we did
not ﬁnd any difference in rate of progression between
the mildemoderate AD and DLB groups over a 1-year
period of observation. Cognitive decline is only one
aspect of dementia and other impairments may in fact
be more important and disabling.
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